Verizon Business (NYSE:VZ) has been appointed to operate the global network infrastructure of Astellas Pharma Inc. (OTC:ALPMY). As a result of the network transformation, Astellas (OTC:ALPMY) will be able to leverage sophisticated technology to reduce drug development timetables and healthcare costs and generate new income prospects for the Japanese multinational pharmaceutical company.
Astellas (OTC:ALPMY) is a multinational pharmaceutical business headquartered in Tokyo, Japan, engaged in the research, development, manufacturing, and marketing of revolutionary new pharmaceuticals with the mission to Stand at the forefront of healthcare change to transform creative science into VALUE for patients. The company has 14,000 employees globally.
The company identifies digital transformation as a critical driver of its business growth. It has begun searching for a global partner to transform all areas of its global technological infrastructure, including the construction, design, and implementation of a next-generation secure network. Precisely, Astellas (OTC:ALPMY) desired a scalable and reliable platform that could manage tens of thousands of devices and endpoints across its 70+ global sites in a virtualized multi-sourced environment.
Verizon Business and Astellas Pharma Inc.
The connection between Verizon Business (NYSE:VZ) and Astellas (OTC:ALPMY) spans over a decade. Astellas successfully implemented Verizon’s Secure Cloud Interconnect (SCI) solution in 2016 to provide a secure, high-bandwidth connection to its Amazon Web Services (AWS) and Microsoft Azure cloud services. Verizon Business is currently tasked with constructing and deploying Astellas’ global integrated network with a comprehensive suite of managed services, including Managed Wide Area Network, Local Area Network, Managed Security Services (MSS), Secure Gateway, and Zero Trust Network Access, and Unified Communications and Collaboration as a Service.
Shinya Suda, Senior Vice President, Information Systems at Astellas (OTC:ALPMY), remarked, From R&D to sales, we are experiencing a massive influx of data and insight throughout our 70 global locations. We want to ensure that our network is future-proof so that we can use cutting-edge technology such as Artificial Intelligence, machine learning, and robotics to make data-driven, patient-beneficial decisions. The restructuring of our network will support the next phase of our growth.
Featured Image: Megapixl @RightFramePhotoVideo
